As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
The fall of Neil Woodford, the UK’s most prominent fund manager in life sciences and biotech, is at last reaching its conclusion – ending the career of a former star investor whose endorsement was once highly valued by UK life sciences companies, but which simply became bad news.
A series of misplaced investment decisions over the last few years came to a head earlier this year, with his flagship Woodford Equity Income Fund (WEIF)
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.
